Geron (GERN) Share-based Compensation (2010 - 2026)
Geron's (GERN) quarterly Share-based Compensation came in at $4.9 million in Q2 2026, down 26.83% year-over-year from $6.8 million in Q2 2025, and up 0.73% quarter-over-quarter from $4.9 million in Q1 2026.
Analysis
Geron (GERN) Share-based Compensation (2010 - 2026) Analysis & Trends
Geron has disclosed Share-based Compensation across 17 years of filings, most recently posting $4.9 million for Q2 2026.
- In Q2 2026, Share-based Compensation fell 26.83% year-over-year to $4.9 million; the TTM figure through Jun 2026 stood at $22.3 million (down 19.86% YoY), while the FY2025 annual figure was $26.7 million, down 64.91% from the prior year.
- Share-based Compensation came in at $4.9 million for Q2 2026 at Geron, up from $4.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $16.4 million in Q2 2024 to a low of $573000.0 in Q2 2023.
- Average Share-based Compensation over 5 years is $5.5 million, with a median of $5.4 million recorded in 2025.
- Year-over-year, Share-based Compensation soared 9852.94% in 2022 and plunged 58.69% in 2025.
- Over 5 years, Share-based Compensation stood at $2.2 million in 2022, then surged by 101.83% to $4.4 million in 2023, then jumped by 53.83% to $6.8 million in 2024, then declined by 15.04% to $5.8 million in 2025, then fell by 14.24% to $4.9 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $4.9 million in Q2 2026, $4.9 million in Q1 2026, and $5.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 4.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.95 Mn |
| Mar 31, 2026 | 4.91 Mn |
| Dec 31, 2025 | 5.77 Mn |
| Sep 30, 2025 | 6.70 Mn |
| Jun 30, 2025 | 6.76 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Dec 31, 2024 | 6.79 Mn |
| Sep 30, 2024 | 6.89 Mn |
| Jun 30, 2024 | 16.37 Mn |
| Mar 31, 2024 | 4.88 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Sep 30, 2023 | 7.20 Mn |
| Jun 30, 2023 | 573,000.00 |
| Mar 31, 2023 | 7.88 Mn |
| Dec 31, 2022 | 2.19 Mn |
| Sep 30, 2022 | 2.06 Mn |
| Jun 30, 2022 | 761,000.00 |
| Mar 31, 2022 | 1.69 Mn |
| Dec 31, 2021 | 2.31 Mn |
| Sep 30, 2021 | 2.01 Mn |